Cystamine

Publication Title: 
Neurobiology of Disease

Huntington's disease (HD) is a lethal, neurodegenerative disorder caused by expansion of the polyglutamine repeat in the Huntingtin gene (HTT), leading to mutant protein misfolding, aggregation, and neuronal death. Feeding a Drosophila HD model cystamine, or expressing a transgene encoding the anti-htt intracellular antibody (intrabody) C4-scFv in the nervous system, demonstrated therapeutic potential, but suppression of pathology was incomplete.

Author(s): 
Bortvedt, S. F.
McLear, J. A.
Messer, A.
Ahern-Rindell, A. J.
Wolfgang, W. J.
Publication Title: 
The Journal of Neuroscience: The Official Journal of the Society for Neuroscience

The precise cause of neuronal death in Huntington's disease (HD) is unknown. Proteolytic products of the huntingtin protein can contribute to toxic cellular aggregates that may be formed in part by tissue transglutaminase (Tgase). Tgase activity is increased in HD brain. Treatment in R6/2 transgenic HD mice, using the transglutaminase inhibitor cystamine, significantly extended survival, improved body weight and motor performance, and delayed the neuropathological sequela. Tgase activity and N(Sigma)-(gamma-L-glutamyl)-L-lysine (GGEL) levels were significantly altered in HD mice.

Author(s): 
Dedeoglu, Alpaslan
Kubilus, James K.
Jeitner, Thomas M.
Matson, Samantha A.
Bogdanov, Misha
Kowall, Neil W.
Matson, Wayne R.
Cooper, Arthur J. L.
Ratan, Rajiv R.
Beal, M. Flint
Hersch, Steven M.
Ferrante, Robert J.
Subscribe to RSS - Cystamine